A trilogy case review highlighting the clinical and pharmacologic applications of mirtazapine in reducing polypharmacy for anxiety, agitation, insomnia, depression, and sexual dysfunction

Primary Care Companion to the Journal of Clinical Psychiatry

Volumn 1, Issue 5, 1999, Pages 142-145

  Barkin, Robert L ^a,b   Chor, Philip N ^a   Braun, Bennett G ^a   Schwer, William A ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b RUSH MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 53149109018     PISSN: 15235998     EISSN: None     Source Type: Journal    
DOI: 10.4088/PCC.v01n0502     Document Type: Article

References (27)

1. de Boer T. The pharmacologic profile of mirtazapine. J Clin Psychiatry 1996;57(suppl 4):19-25
2. Montgomery SA. Safety of mirtazapine: a review. Int Clin Psychopharmacol 1995;10(suppl 4):37-45
3. Nutt D. Mirtazapine: pharmacology in relation to adverse effects. Acta Psychiatr Scand 1997;96(suppl 391):31-37
4. Stimmel GL, Sussman N, Wingard P. Mirtazapine safety and tolerability: analysis of the clinical trials database. Prim Psychiatry 1997;96:82-90
5. Hoes MJ, Zeijpveld JH. Mirtazapine as a treatment for serotonin syndrome [letter]. Pharmacopsychiatry 1996;29:81
6. Barkin RL, Lubenow TR, Bruehl S, et al. Management of chronic pain, part 1. Dis Mon 1996;42:385-456
7. Dubovsky SL. Beyond the serotonin reuptake inhibitors: rationales for the development of new serotonergic agents. J Clin Psychiatry 1994;55(2, suppl):34-44
8. Fawcett J, Barkin RL. A meta-analysis of eight randomized, double-blind, controlled clinical trials of mirtazapine for the treatment of patients with major depression and symptoms of anxiety. J Clin Psychiatry 1998;59:123-127
9. Shader RI, Greenblatt DJ. Use of benzodiazepines in anxiety disorders. N Engl J Med 1993;328:1398-1405
10. Pohl R, Yeragani VK, Balon R, et al. The jitteriness syndrome in panic disorder patients treated with antidepressants. J Clin Psychiatry 1988;49:100-104
11. Wirshing WC, Van Putten T, Rosenberg J, et al. Fluoxetine, akathisia, and suicidality: is there a causal connection? Arch Gen Psychiatry 1992;49:580-581
12. Janicak PG, Davis JM, Preskorn SH, et al. Principles and Practice of Psychopharmacotherapy. 2nd ed. Philadelphia, Pa: Williams & Wilkins; 1998
13. Sitsen JMA, Moors J. Mirtazapine, a novel antidepressant, in the treatment of anxiety symptoms: results from a placebo-controlled trial. Drug Invest 1994;8:339-344
14. Davis JM. Is mirtazapine a better antidepressant than the SSRIs? Essen Psychopharmacol 1998;2:309-330
15. Patterson WM. Fluoxetine-induced sexual dysfunction [letter]. J Clin Psychiatry 1993;54:71
16. Gelenberg AJ, Laukes C, McGahuey C, et al. Mirtazapine substitution in SSRI-induced sexual dysfunction. Biol Psychiatry 1998;43:104S. 1S-1335
17. Farah A. Lack of sexual adverse effects with mirtazapine [letter]. Am J Health Syst Pharm 1998;55:2195-2196
18. Farah A. Relief of SSRI-induced sexual dysfunction with mirtazapine treatment [letter]. J Clin Psychiatry 1999;60:260-261
19. Davis J, Barkin RL. Clinical pharmacology of mirtazapine: revisited [letter]. Am Fam Physician 1999;60:1101
20. Stimmel GL, Dopheide JA, Stahl SM. Mirtazapine: an antidepressant with noradrenergic and specific serotonergic effects. Pharmacotherapy 1997;17:10-21
21. Fawcett I, Kravitz HM. Anxiety syndromes and their relationship to depressive illness. J Clin Psychiatry 1983;44(8 pt 2):8-11
22. Nutt D. Management of patients with depression associated with anxiety symptoms. J Clin. Psychiatry 1997;58(suppl 8):11-16
23. Fawcett J. The detection and consequences of anxiety in clinical depression. J Clin Psychiatry 1997;58(suppl 8):35-40
24. Wheatley DP, van Moffaert M, Timmerman L, et al. Mirtazapine efficacy and tolerability in comparison with fluoxetine in patients with moderated to severe major depressive disorder. J Clin Psychiatry 1998:59:306-312
25. Winokur A, Sateia MJ, Hayes JB, et al. Effects of mirtazapine on sleep continuity and sleep architecture in depressed patients: a pilot study [poster]. Presented at the 53rd annual meeting of the Society of Biological Psychiatry; May 27-30, 1998; Toronto, Canada
26. Lader M. Rebound insomnia and newer hypnotics. Psychopharmacology 1992;108:248-255
27. Fawcett J, Barkin RL. Review of the results from clinical studies on the efficacy, safety, and tolerability of mirtazapine for the treatment of patients with major depression. J Affect Disord 1998;51:267-285